API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Canagliflozin inhibits SGLT2 which reduces reabsorption of filtered glucose thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, intestinal absorption of glucose and improves insulin sensitivity.
Lead Product(s): Canagliflozin,Metformin
Therapeutic Area: Endocrinology Product Name: Canagliflozin/Metformin Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Canagliflozin
Therapeutic Area: Endocrinology Product Name: Canagliflozin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Adults with heart failure who took canagliflozin, a medication originally developed to treat type 2 diabetes, reported improvements in their heart failure symptoms whether or not they also had type 2 diabetes.
Lead Product(s): Canagliflozin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: JNJ-28431754
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Janssen Scientific Affairs
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2021
Details:
Tai Tien Pharmaceuticals has obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA.
Lead Product(s): Canagliflozin
Therapeutic Area: Nephrology Product Name: Canaglu
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Tai Tien Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
The EC approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which achieved pre-specified efficacy criterion.
Lead Product(s): Canagliflozin
Therapeutic Area: Nephrology Product Name: Invokana
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2020
Details:
The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy criterion.
Lead Product(s): Canagliflozin
Therapeutic Area: Nephrology Product Name: Invokana
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2020
Details:
Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on a conclusive signal of efficacy in the prevention of the primary endpoint.
Lead Product(s): Canagliflozin
Therapeutic Area: Nephrology Product Name: Invokana
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020